abstract |
Disclosed is a composition containing recombinant iduronate-2-sulfatase (IDS). The glycosylation profile and the content of formylglycine in the composition of IDS are different from Elapraz, and it has superior pharmaceutical efficacy and is safer than a conventional agent and, thus, can be effectively used for the treatment of Hunter syndrome. |